| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036384 |
| Receipt No. | R000041433 |
| Scientific Title | A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function |
| Date of disclosure of the study information | 2020/10/20 |
| Last modified on | 2022/10/04 (Ver. 2) |
| Basic information | ||
| Public title | A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function | |
| Acronym | A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function | |
| Scientific Title | A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function | |
| Scientific Title:Acronym | A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function | |
| Region |
|
|
| Condition | |||
| Condition | Healthy volunteers | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate the effects of fish oil containing DHA on the preservation of renal function |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes of markers of renal function (eGFR, creatinine) |
| Key secondary outcomes | Changes of markers of renal function (creatinine clearance), Changes of markers relating to renal impairment (urinary L-FABP, albumin/creatinine, NAG, KIM-1, angiotensinogen), Changes of blood pressure, glucose metabolic markers (HbA1c, blood glucose), lipid markers (LDL-C, TG, HDL-C), body weight and other clinical test values
|
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of capsules (fish oil containing DHA) for 24 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1) Males between the ages of 45 and 74 years old
2) Subjects whose results at the screening examination fall into either of the following ・ Systolic blood pressure >= 130 mmHg or diastolic blood pressure >= 85 mmHg ・ Fasting blood glucose >= 110 mg/dL ・ Spot urine albumin/creatinine >= 10 mg/g・Cr |
|||
| Key exclusion criteria | 1) Subjects who take medicines having the effect on the present study (diuretics, antihypertensive agents, SGLT2 inhibitors, warfarin, uricosuric agents, etc.)
2) Subjects who take foods for specified health uses, foods with function claims labeled or supplements (reducing triglycerides, blood pressure, blood glucose and having the effects on dysuria) which can affect the data in a main study 3) Subjects with dysuria who cannot collect their urine 4) Subjects receiving a medical history of serious liver disorder, renal disorder or heart diseases 5) Subjects receiving a medical treatment or having a medical history of hepatitis 6) Subjects who have terrible anemia 7) Subjects who have addiction to alcohol 8) Subjects who need assistance by others and who cannot walk independently 9) Subjects who are bleeding (hemophilia, capillary vulnerability, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.) 10) Subjects who have the possibility of developing allergic symptoms by the test food 11) Subjects having a medical history of hypersensitivity to the test food 12) Subjects currently participating in other clinical trials or planning to participate in other clinical trials during the examination period 13) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 14) Subjects deemed unsuitable by the investigator |
|||
| Target sample size | 35 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Maruha Nichiro Corporation | ||||||
| Division name | Central Research Institute | ||||||
| Zip code | 300-4295 | ||||||
| Address | 16-2, Wadai, Tsukuba, Ibaraki | ||||||
| TEL | 029-864-6708 | ||||||
| s-ashida@maruha-nichiro.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Soiken Inc. | ||||||
| Division name | R&D Division | ||||||
| Zip code | 560-0082 | ||||||
| Address | Senri Life Science Center 13F,1-4-2, Shinsenre-higashimachi, Toyonaka, Osaka | ||||||
| TEL | 06-6871-8888 | ||||||
| Homepage URL | |||||||
| sugino@soiken.com | |||||||
| Sponsor | |
| Institute | Soiken Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Maruha Nichiro Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB of Fukuda Clinic |
| Address | Shin-Osaka Brick Building 2F, 1-6-1, Miyahara, Yodogawa-ku, Osaka, Osaka |
| Tel | 06-6398-0203 |
| fukudaclinicIRB@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000041433 |